This program will focus on heightened risk factors for publicly traded companies when providing information to investors and provide insights about such risk factors using the recent securities fraud class action filed against Inovio Pharmaceuticals Inc. and its CEO as an example. The faculty will review the theories of securities fraud commonly relied upon, such as the fraud-on-the market theory, along with measures to avoid or limit these risks.